Worsening Central Sarcopenia and Increasing Intra‐Abdominal Fat Correlate with Decreased Survival in Patients with Adrenocortical Carcinoma
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Background: Accurate prediction of survival from adrenocortical carcinoma (ACC) is difficult and current staging models are unreliable. Central sarcopenia as part of the cachexia syndrome is a marker of frailty and predicts mortality. This study seeks to confirm that psoas muscle density (PMD), lean psoas muscle area (LPMA), lumbar skeletal muscle index (LSMI), and intra‐abdominal (IA) or subcutaneous fat (SC) can be used in combination to more accurately predict survival in ACC patients. Methods: PMD, LPMA, IA, and SC fat were measured on serial CT scans of patients with ACC. Clinical outcome was correlated with quantitative data from patients with ACC and analyzed. A linear regression model was used to describe the relationship between PMD, LPMA, LSMI, IA, and SC fat, time to recurrence, and length of survival according to tumor stage. Results: One hundred twenty‐five ACC patients (94 females) were treated from 2005 to 2011. Significant morphometric predictors of survival include PMD, LPMA, and IA fat (p ≤ 0.0001, ≤0.0024, <0.0001, respectively) and improve prediction of survival compared to using stage alone. A 100‐mm 2 increase in LPMA confers an 8 % lower hazard of death. LSMI does not change significantly between stages (p = 0.3196). Conclusion: Decreased PMD, LPMA, and increased IA fat suggest decreased survival in ACC patients and correlate with traditional staging systems. A more precise prediction of survival may be achieved when staging systems and morphometric measures are used in combination. Serial measurements of morphometric data are possible. The rate of change of these variables over time may be more important than the absolute value.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prado, C. M., Lieffers, J. R., McCargar, L. J., Reiman, T., Sawyer, M. B., Martin, L., & Baracos, V. E. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70153-0 · Cited by 3,238
Mourtzakis, M., Prado, C. M. M., Lieffers, J. R., Reiman, T., McCargar, L. J., & Baracos, V. E. (2008) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/h08-075 · Cited by 2,224 · cited 1×
“Although bioelectrical impedance analysis and DEXA have been used historically to quantify fat and muscle mass, CT has emerged as a more precise and accessible modality to quantify body composition and assess tumor changes [16, 17].”
MethodGoodpaster, B. H., Kelley, D. E., Thaete, F. L., He, J., & Ross, R. (2000) · Journal of Applied Physiology · doi:10.1152/jappl.2000.89.1.104 · Cited by 947
Adrenocortical carcinoma in the United States: Treatment utilization and prognostic factors
Bilimoria, K. Y., Shen, W. T., Elaraj, D., Bentrem, D. J., Winchester, D. J., Kebebew, E., & Sturgeon, C. (2008) · Cancer · doi:10.1002/cncr.23886 · Cited by 493
Radiotherapy in adrenocortical carcinoma
Polat, B., Fassnacht, M., Pfreundner, L., Guckenberger, M., Bratengeier, K., Johanssen, S., Kenn, W., Hahner, S., Allolio, B., & Flentje, M. (2009) · Cancer · doi:10.1002/cncr.24331 · Cited by 189 · cited 1×
“Completeness of resection and use of adjuvant mitotane and external beam radiotherapy improve survival in selected populations, but indications for use are still not well defined or uniformly applied [3, 4].”
BackgroundAdjuvant and definitive radiotherapy for adrenocortical carcinoma
Sabolch, A., Feng, M., Griffith, K., Hammer, G., Doherty, G., & Ben-Josef, E. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.04.030 · Cited by 115 · cited 1×
“Completeness of resection and use of adjuvant mitotane and external beam radiotherapy improve survival in selected populations, but indications for use are still not well defined or uniformly applied [3, 4].”
BackgroundSelf-citationProposal for modification of the ENSAT staging system for adrenocortical carcinoma using tumor grade
Miller, B. S., Gauger, P. G., Hammer, G. D., Giordano, T. J., & Doherty, G. M. (2010) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-010-0698-y · Cited by 84 · cited 2×
“Stage I and II patients were combined together due to the small number of stage I patients, and previous studies have also suggested that stage I and II patients can be combined for survival analysis due to the lack of discriminatory ability of the staging systems [1, 13].”
Background
Cited by
Batsis, J. A., Mackenzie, T. A., Barre, L. K., Lopez-Jimenez, F., & Bartels, S. J. (2014) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2014.117 · Cited by 479
Bozzetti, F. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx271 · Cited by 323
van Vugt, J. L. A., Levolger, S., Gharbharan, A., Koek, M., Niessen, W. J., Burger, J. W. A., Willemsen, S. P., de Bruin, R. W. F., & IJzermans, J. N. M. (2017) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12158 · Cited by 217
Ozola Zalite, I., Zykus, R., Francisco Gonzalez, M., Saygili, F., Pukitis, A., Gaujoux, S., Charnley, R. M., & Lyadov, V. (2015) · Pancreatology · doi:10.1016/j.pan.2014.11.006 · Cited by 174
Sjøblom, B., Grønberg, B. H., Wentzel-Larsen, T., Baracos, V. E., Hjermstad, M. J., Aass, N., Bremnes, R. M., Fløtten, Ø., Bye, A., & Jordhøy, M. (2016) · Clinical Nutrition · doi:10.1016/j.clnu.2016.03.010 · Cited by 143
“The negative prognostic impact of reduced SMD has recently come up in several other cancer populations, including patients with different solid tumours [13], malignant melanoma [20], adrenocortical carcinoma [21], metastatic renal cell carcinoma [22] and pancreatic cancer or distal cholangiocarcinomas [26].”
Background
Metadata
- Authors
- Miller, B. S., Ignatoski, K. M., Daignault, S., Lindland, C., Doherty, M., Gauger, P. G., Hammer, G. D., Wang, S. C., Doherty, G. M., & The University of Michigan Analytical Morphomics Group
- Venue
- World Journal of Surgery
- Publisher
- Wiley
- Published
- 2012-04-19
- Volume
- 36
- Issue
- 7
- Pages
- 1509-1516
- ISSN
- 0364-2313 (ISSN-L)
- 1432-2323
- OpenAlex
- W2107355189
- Cited by
- 76
- References
- 7
- FWCI
- 4.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.